Gachon University Gil Medical Center

The Korean Dementia Association reassures on Leqembi's safety, noting rare side effects like brain hemorrhage. Phase 3 trial results show Leqembi delayed Alzheimer’s progression by 27%, leading to MFDS approval in Korea. Despite EU and Australia's refusal to approve due to ARIA concerns, Korean data reveals fewer side effects in Asians, with only 6.5% incidence of cerebral edema among Korean participants.